Literature DB >> 19919593

Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study.

Celia J A Morgan1, Leslie Muetzelfeldt, H Valerie Curran.   

Abstract

BACKGROUND: 'Recreational' use of ketamine is spreading rapidly among young people. In healthy individuals an acute dose of the N-methyl D-aspartate (NMDA) receptor antagonist ketamine induces marked psychosis-like effects and cognitive impairments, but little is known about the long-term effects of the drug. AIMS: To evaluate the long-term neuropsychiatric or cognitive consequences.
METHODS: A total of 150 individuals were assessed, 30 in each of five groups: frequent ketamine users, infrequent ketamine users, abstinent users, polydrug controls and non-users of illicit drugs. Twelve months later, 80% of these individuals were re-tested.
RESULTS: Cognitive deficits were mainly observed only in frequent users. In this group, increasing ketamine use over the year was correlated with decreasing performance on spatial working memory and pattern recognition memory tasks. Assessments of psychological wellbeing showed greater dissociative symptoms in frequent users and a dose-response effect on delusional symptoms, with frequent users scoring higher than infrequent, abstinent users and non-users, respectively. Both frequent and abstinent using groups showed increased depression scores over the 12 months.
CONCLUSIONS: These findings imply that heavy use of ketamine is harmful to aspects of both cognitive function and psychological wellbeing. Health education campaigns need to raise awareness among young people and clinicians about these negative consequences of ketamine use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19919593     DOI: 10.1111/j.1360-0443.2009.02761.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  84 in total

Review 1.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

Review 2.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 3.  Ketamine for treatment-resistant unipolar depression: current evidence.

Authors:  Sanjay J Mathew; Asim Shah; Kyle Lapidus; Crystal Clark; Noor Jarun; Britta Ostermeyer; James W Murrough
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

4.  The P1 visual-evoked potential, red light, and transdiagnostic psychiatric symptoms.

Authors:  Jeffrey S Bedwell; Christopher C Spencer; Chi C Chan; Pamela D Butler; Pejman Sehatpour; Joseph Schmidt
Journal:  Brain Res       Date:  2018-03-03       Impact factor: 3.252

5.  Pharmacological and non-pharmacological factors that regulate the acquisition of ketamine self-administration in rats.

Authors:  Marco Venniro; Anna Mutti; Cristiano Chiamulera
Journal:  Psychopharmacology (Berl)       Date:  2015-09-21       Impact factor: 4.530

Review 6.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

7.  Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Authors:  Lawrence P Carter; Bethea A Kleykamp; Roland R Griffiths; Miriam Z Mintzer
Journal:  Psychopharmacology (Berl)       Date:  2012-10-25       Impact factor: 4.530

8.  Juvenile exposure to ketamine causes delayed emergence of EEG abnormalities during adulthood in mice.

Authors:  R E Featherstone; L R Nagy; C G Hahn; S J Siegel
Journal:  Drug Alcohol Depend       Date:  2013-09-27       Impact factor: 4.492

9.  Cyclosporine exacerbates ketamine toxicity in zebrafish: Mechanistic studies on drug-drug interaction.

Authors:  Bonnie L Robinson; Melanie Dumas; Syed F Ali; Merle G Paule; Qiang Gu; Jyotshna Kanungo
Journal:  J Appl Toxicol       Date:  2017-06-01       Impact factor: 3.446

10.  Acetyl L-carnitine targets adenosine triphosphate synthase in protecting zebrafish embryos from toxicities induced by verapamil and ketamine: An in vivo assessment.

Authors:  Xiaoqing Guo; Melanie Dumas; Bonnie L Robinson; Syed F Ali; Merle G Paule; Qiang Gu; Jyotshna Kanungo
Journal:  J Appl Toxicol       Date:  2016-05-18       Impact factor: 3.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.